Small molecule · Inhibitor of p38 MAPK alpha/beta (MAPK14) · developed by Fulcrum Therapeutics
Losmapimod is an orally bioavailable inhibitor of the alpha and beta isoforms of p38 mitogen-activated protein kinase. It suppresses p38 alpha/beta signaling, which reduces production of proinflammatory cytokines such as TNF-alpha, IL-1, IL-6 and IL-8. It is studied in COVID-19 and facioscapulohumeral muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05397470 | Phase 3 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Terminated | FULC |
| NCT04511819 | Phase 3 | COVID-19 | Terminated | FULC |
| NCT05002231 | Phase 1 | Healthy Adult Subjects | Completed | FULC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19Facioscapulohumeral Muscular Dystrophy (FSHD)Healthy Adult Subjects
Updated Nov 15, 2026. Something wrong or missing? Report it on the FULC page.
See FULC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FULC catalysts and pipeline →